321
Participants
Start Date
January 31, 2008
Primary Completion Date
December 31, 2008
Study Completion Date
June 30, 2009
COL-121
75 µg/g COL-121 Ointment
50 µg/g Calcipotriene Ointment
50 µg/g Calcipotriene Ointment
Placebo
Placebo
COL-121
150 µg/g COL-121 Ointment
COL-121
300 µg/g COL-121 Ointment
Philadelphia Institute of Dermatology, Flourtown
The Education & Research Foundation, Inc., Lynchburg
MedaPhase, Inc., Newnan
International Dermatology Research, Inc., Miami
Dermatology Specialists, Louisville
Michigan Center for Skin Care Research, Clinton Township
Grekin Skin Institute, Warren
Dermatology Associates of San Antonio, San Antonio
DermResearch, Inc., Austin
Cherry Creek Research, Inc., Denver
Longmont Medical Research Network, Longmont
Dermatology Research Center, Salt Lake City
Academic Dermatology Associates, Albuquerque
Dermatology Research Associates, Los Angeles
Dermatology Specialists, Inc., Vista
Skin Surgery Medical Group, Inc., San Diego
East Bay Dermatology Medical Group, Fremont
Northwest Cutaneous Research Specialists, Portland
Premier Clinical Research, Spokane
The Savin Center, PC, New Haven
Lead Sponsor
Deltanoid Pharmaceuticals
INDUSTRY